Products for Out-Licensing

Products Available for Out-Licensing

NAL develops novel dosage forms and proprietary drug delivery systems based on Company’s captive Drug Delivery System (“DDS”) technologies. NAL expects to partner with pharmaceutical companies for the development and commercialization of the NAL products in global markets.

The partial listing of NAL’s products is outlined below. As we have not disclosed the complete list of our proprietary DDS products under development, please write to us at [email protected] to know more about NAL’s products and partnering opportunities.

Oncology and Supportive Oncology
 
Products Marketed or Under Development (Partial Listing)
Proposed US Filing
NAL1845 Albumin-bound Paclitaxel Injection for Cancers
ANDA
NAL1872 Doxorubicin Liposome Injection for Cancers
ANDA
NAL1877 Leuprolide Acetate 1/3/4/6-Month Injection for Prostate Cancer
ANDA
NAL1853 Goserelin Acetate 1/3 Month Implant for Breast and Prostate Cancers
ANDA
NAL1866 Octreotide Acetate 4-Week Long-Acting Injection for Acromegaly/Carcinoid Tumors
ANDA
NAL1868 Lanreotide Acetate 4-Week Long-Acting Injection for Acromegaly/Carcinoid Tumors
ANDA
NAL1873 Irinotecan Liposome Injection for Pancreatic Cancer
ANDA
Top